This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Avodart

Composition 1

The active component of Avodart is the 5-alpha-reductase dutasteride. Each capsule contains 0.5 mg of dutasteride.

Dutasteride:

Indication 1

Avodart is indicated for the treatment and control of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to improve symptoms, reduce the risk of urinary retention, and reduce the risk of the need for BPH-related surgery.

References:

  1. Avodart Prescribing Information, Version 01.

Trade marks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.